MBX Biosciences
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | $188m | IPO |
| Total Funding | 000k | ||
Frazier Healthcare Partners(exited)
OrbiMed(exited)
NEA(exited)
BioCrossroads(exited)
Twilight Venture Partners(exited)
Wellington Management(exited)
Norwest Venture Partners(exited)
RA Capital Management(exited)
Frazier Life Sciences(exited)
Driehaus Capital Management(exited)
T. Rowe Price(exited)
Deep Track Capital(exited)
| USD | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.